Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Combined viral–immune–enzymatic network is a systems biology framework, notably described in research regarding COVID-19 (Sahoo et al., 2021, Processes), that integrates viral kinetics, host immune responses, and enzymatic pathways. This model maps the interactions between SARS-CoV-2, the innate and adaptive immune systems, and the Renin-Angiotensin System (RAS), specifically focusing on the role of the ACE2 enzyme as both a viral entry point and a regulator of inflammation. By simulating these interconnected processes, the network helps identify how viral load and immune signaling contribute to disease states like cytokine storms and respiratory distress. While it provides a comprehensive view of disease pathology, it is a conceptual and mathematical model rather than a single molecular target. Therefore, it is used for predicting therapeutic outcomes and understanding systemic interactions rather than being a direct site for drug binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Combined viral–immune–enzymatic network.